Trastuzumab emtansine is named as a drug or biological intervention in 18 clinical trials in our China, USA, UK, Ireland and India trial registers, 6 of which are recruiting. Lead sponsors include Hoffmann-La Roche (3), Daiichi Sankyo (2) and Fudan University (2). Registered phases: Phase 3, Phase 2, Phase 1/2, Phase 1 and Observational. Conditions studied include HER2-positive Breast Cancer; Breast Cancer; Metastatic Breast Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| HER2-positive Breast Cancer | 5 |
| Breast Cancer | 2 |
| Metastatic Breast Cancer | 2 |
| HER2-Positive Primary Breast Cancer | 1 |
| Residual Invasive Breast Cancer | 1 |
| HER2 Mutant Non-small Cell Lung Cancer | 1 |
| HER2-positive Metastatic Breast Cancer | 1 |
| HER2 Gene Mutation | 1 |
| HER2 Amplification | 1 |
| Advanced Solid Tumor | 1 |
| Locally Advanced Solid Tumor | 1 |
| Metastatic Solid Tumor | 1 |
| Platinum-resistant Ovarian Cancer | 1 |
| Advanced or Metastatic Pancreatic Adenocarcinoma | 1 |
| Advanced or Metastatic Breast Cancer (BC) | 1 |
| Breast Cancer Invasive | 1 |
| Metastatic Gastric Adenocarcinoma | 1 |
| Gastroesophageal Junction Adenocarcinoma | 1 |
| Esophageal Adenocarcinoma | 1 |
| Solid Tumors | 1 |
| Neoplasm Metastasis | 1 |
| Ovarian Cancer | 1 |
| Gastric Cancer | 1 |
| Second-line Treatment | 1 |
| Lead sponsor | Trials |
|---|---|
| Hoffmann-La Roche | 3 |
| Daiichi Sankyo | 2 |
| Fudan University | 2 |
| Seagen, a wholly owned subsidiary of Pfizer | 1 |
| Enliven Therapeutics | 1 |
| Ascendis Pharma Oncology Division A/S | 1 |
| DualityBio Inc. | 1 |
| GeneQuantum Healthcare (Suzhou) Co., Ltd. | 1 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 1 |
| Shanghai Jiao Tong University School of Medicine | 1 |
| Boehringer Ingelheim | 1 |
| Genentech, Inc. | 1 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 1 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 1 |
| Register | Trastuzumab emtansine trials |
|---|---|
| Clinical trials in China | 15 |
| Clinical trials in USA | 10 |
| Clinical trials in UK | 8 |
| Clinical trials in Ireland | 1 |
| Clinical trials in India | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Trastuzumab emtansine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Trastuzumab emtansine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.